Stockreport

Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology [Yahoo! Finance]

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF Preclinical data show antitumor activity and enhanced sensitivity to chemotherapies and radiotherapy across multiple NRF2-dependent cancer models Research provides fo [Read more]